Novo Nordisk or Eli Lilly: First GLP-1 cardiovascular drug ad campaign in 2026: Both launch same day

Resolution

Rule

Resolves based on which company (Novo Nordisk or Eli Lilly) is first to launch a direct-to-consumer advertising campaign in the United States explicitly promoting a GLP-1 drug (e.g., Ozempic, Wegovy, Mounjaro, or Zepbound) for a cardiovascular indication (heart attack reduction, cardiovascular death reduction, or similar heart-health claim approved by FDA). Evidence must be a publicly viewable TV ad, digital ad, or press release from the manufacturer published during calendar year 2026. Resolution source: the manufacturer's official newsroom or a publicly accessible ad archive such as the FDA's Bad Ad program page or iSpot.tv. 'Novo Nordisk first' resolves YES if Novo Nordisk publishes such a campaign before Eli Lilly does. 'Eli Lilly first' resolves YES if Eli Lilly publishes such a campaign before Novo Nordisk does. 'Both launch simultaneously or same day' resolves YES if both companies launch on the same calendar date. 'Neither launches' resolves YES if no qualifying campaign is publicly confirmed by December 31, 2026.

Source: https://www.novonordisk-us.com/media/news-archive.html

Resolves by Apr 8, 2027.